|Bid||8.97 x 1200|
|Ask||18.36 x 1000|
|Day's Range||11.92 - 12.48|
|52 Week Range||8.48 - 21.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 07, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.20|
The big marquee names tend to get the most love and attention from investors and analysts alike. Monoliths like Apple, Amazon and Facebook have provided incredible returns for investors over the years. While there is room for further upside, the question for growth minded investors is how much further can these mega-caps really soar.So, have latecomers missed the boat on these ubiquitous corporations as far as sky-high returns are concerned? Possibly. But no matter, there’s always opportunity for those willing to seek it out. The big names get all the press, but some of the little guys have been making giant strides in the market, too. What’s more, the lower valuation means these companies further down the food chain have ample room for growth.With this in mind, we used TipRanks’ Stock Screener tool to find three tickers that not only grew substantially in 2019, but also boast huge upside potential in the year ahead. Let’s dig a little deeper.Evofem Biosciences Inc. (EVFM)First up, we come across a small company in the biotech space. In fact, with a market cap of just $264.5 million, Evofem qualifies as a micro-cap. If things work out for the women's sexual and reproductive health products company as some on the Street predict, it won’t be staying in small-cap territory for long.Last year, Evofem added an impressive 47% to its share price. Investors were excited about the progress of the company’s lead candidate Amphora, a non-hormonal woman-controlled vaginal gel. The product completed a Phase 3 clinical trial for the prevention of pregnancy last year, with top-line data meeting the primary endpoint. Evofem has resubmitted a marketing application to the FDA for the approval of Amphora for a contraception indication, with a PDUFA date set for May 25 (the company received a CRL for the application in 2016). Adding to the good news, Amphora is also being evaluated in clinical trials for the prevention of chlamydia and gonorrhea in women. Positive top-line results from the AMPREVENCE Phase 2b trial were announced in December.Oppenheimer’s Leland Gershell likes what he’s seeing when it comes to Evofem. The 5-star analyst recommends “investors take advantage of current levels to build a position in EVFM."Gershell further added, “Amphora's Phase 2b trial in STI prevention, which demonstrated significant reductions in chlamydia and gonorrhea infection in sexually-active women, came as a positive surprise as investors had been focused on the initial contraception opportunity. We expect eventual label expansion to STI prevention to be enabled by a single confirmatory trial, to begin in 2H20. With Amphora set to be a non-hormonal, use-on-demand contraceptive as well as the only non-barrier method to prevent sexually-transmitted infections, we have revised our projections to capture the incremental STI opportunity.”The positive data prompted Gershell to reiterate an Outperform rating on Evofem and give the price target a considerable increase - from $11 to $20, as it happens. The implications? Possible upside of a sky scraping 254%. (To watch Gershell’s track record, click here)Two fellow analysts tracked over the last three months concur. Therefore, Evofem’s additional Buy ratings coalesce into a Strong Buy consensus rating. While not quite as mercurial as Gershell’s thesis, the average price target of $14.33 indicates possible upside of an impressive 154%. (See Evofem stock analysis on TipRanks) Magenta Therapeutics Inc. (MGTA)If you’re looking for growth stocks, you could do a lot worse than Magenta Therapeutics. The small-cap’s share price increased by a massive 162% in 2019. Boosted by positive pipeline updates and encouraging data, the share price was sent soaring. 2020 has started out rather more tentatively for Magenta – the stock has pulled back by 19% since the start of the year. Some on the Street, though, believe now is the right time to pull the trigger on this promising biotech.Magenta’s focus is on the use of stem cell transplants to reset patients’ immune systems and, therefore, cure autoimmune diseases, blood cancers and genetic diseases. Currently, radiation and chemotherapy are more widely used to kill disease-causing cells, which in turn, can lead to unwanted side effects such as toxicity and infertility, a situation Magenta hopes to rectify.The company has several candidates in various stages of development. Its lead candidate is CD117-ADC, a drug designed to enable curative stem cell transplant or gene therapy by removing the genetically mutated cells in the bone marrow that cause certain genetic diseases. Preclinical data has shown promising results, and management expects to present initial clinical data for MGTA-117 in 2021.BTIG’s Amanda Murphy sees no reason for the recent sell-off and suggests investors buy on the weakness. Murphy said, “In our view, the future of the company is dependent on the success of its conditioning programs. We elected to be conservative in our market model by limiting the addressable market for these products to indications where the procedure is already well-established and considered standard of care (i.e., blood cancers); however, we see considerable upside if Magenta is able to increase adoption in indications where the procedure is not widely used despite being the only curative treatment option (i.e., autoimmune diseases and hemoglobinopaties). There is also potential for these programs to be used prior to stem cell gene therapy.”Accordingly, then, Murphy reiterated a Buy rating on Magenta along with a price target of $20. A handsome gain of 62% could be heading investors’ way should her price target materialize over the next year. (To watch Murphy’s track record, click here)Out on the Street, only two other analysts currently have a view on the promising biotech. One suggests a Buy, while the other recommends a Hold. Added together, Magenta receives a Moderate Buy consensus rating. The average price target of $19 suggests possible upside of a plentiful 54%. (See Magenta stock analysis on TipRanks) DHT Holdings (DHT)Although not quite as mercurial as Magenta’s 2019, DHT Holdings’ gains in 2019 are nothing to be sniffed at. An increase of 96% would be considered an extremely successful year in anyone’s book. So far in 2020, though, the Bermuda-based oil tanker owner-operator is sailing on choppy waters; the share price is down by 32% year-to-date.New shipping regulation, which came into effect at the start of the year, in addition to sanctions on China’s COSCO Dalian shipping unit (for transporting Iranian crude oil) sent VLCC spot shipping rates through the roof last year. Tanker rates, though, have gone down in 2020. Add to this congestion in China ports, the uncertainty amidst the coronavirus scare and an earnings miss in the last quarterly report as additional reasons for downward pressure on the stock this year.Right now, the tanker market is in the midst of a perfect storm of uncertainty and seasonality. However, Evercore’s Jonathan Chappell expects the situation to “eventually correct amid a strong fundamental backdrop.”Chappell said, “Even with rates declining meaningfully amid usual seasonal refinery demand softness and the initial panic regarding the coronavirus, DHT is still set up to generate record profitability and robust dividends in both 2020 and 2021. Unless the virus ends up being a black swan event that hurts global oil demand by one million barrels per day or more for an extended period of time, the muted orderbook should provide a buffer to crude tanker rates.”What does this mean for investors, then? It means Chappell kept his Outperform rating on DHT as is. The price target, though, comes down a notch, from $12 to $11. The new figure still implies substantial upside potential of 97%. (To watch Chappell’s track record, click here)With 2 Buys and 1 Hold, the consensus on the Street is that DHT is a Moderate Buy. Should the average price target of $8.93 be met over the coming months, investors will be taking home a 60% profit. (See DHT stock analysis on TipRanks)
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 13th, 2020, at 11:00 a.m. ET at the St. Regis Hotel in New York, NY.
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the expansion of its senior leadership with two new strategic hires, Kristen Stants as Chief People Officer and Li Malmberg, Ph.D., as Senior Vice President, Head of Manufacturing.
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today highlighted recent progress across several programs and outlined goals for 2020. These updates will be discussed during a webcast presentation at the 38th annual J.P. Morgan Healthcare Conference on Wednesday, January 15th at 11:30 a.m. PT (2:30 p.m. ET).
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company is scheduled to present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15th, 2020 at 11:30 a.m. PT (2:30 p.m. ET), immediately followed by a Q&A session.
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
Biotechs represent some of the most difficult to gauge investment opportunities on the Street. This is because shares can make big moves in either direction given a single catalyst, making these stocks more volatile in nature. Having said that, more risk-tolerant investors are constantly being drawn to biotechs as the rewards can be staggering.With investor focus locked in on the space, Goldman Sachs took a closer look at the industry as a whole, writing in a recent note to clients that the landscape is improving.“With healthcare policy and the macro backdrop becoming less of a headwind to the group relative to the concerns that pressured the XBI in late 3Q19, we see fundamentals and stock picking returning to the forefront, supported in part by a recent uptick in M&A activity,” Goldman Sachs' Paul Choi stated.Against this backdrop, Choi reminds investors that not all biotech stocks are bound for greatness. Specifically, he points to 3 names with very different growth prospects, starting coverage on one as a Buy, one as a Hold and the other as a Sell.Bearing this in mind, we used TipRanks.com to get the full scoop on the good, the bad and the ugly of the biotech industry. Here’s what we found out.Kiniksa Pharmaceuticals (KNSA)Kiniksa Pharmaceuticals, which just scored an upgrade from Goldman Sachs, wants to meet the large unmet need of patients suffering from autoinflammatory and autoimmune diseases. While shares have fallen year-to-date, Choi argues that the risk/reward profile looks promising ahead of key upcoming catalysts, possibly leading to a reappraisal.Choi highlights its pipeline as a point of strength given the significant unmet need of patients with recurrent pericarditis (RP), giant cell arteritis (GCA) and prurigo nodularis (PN).“While we believe that investors are waiting for clinical de-risking of KNSA’s assets, we recommend positioning in advance of these 2020 events as we anticipate that more value will be assigned to the pipeline upon the data read outs, as we are optimistic regarding KNSA’s sole focus on indications with limited treatment options and comparatively low competitive intensity,” the analyst explained.To top it off, the company is slated to release pivotal Phase 3 data for rilonacept, its most advanced asset, in the second half of 2020. Choi notes that as it received approval for CAPS (cryopyrin-associated periodic syndromes) treatment and the prior Phase 2 data was favorable, “we think investors already view the Phase 3 data and potential approval optimistically and do not view the data as a large inﬂection point for the stock.”He does however cite KNSA’s mavrilimumab drug for the treatment of giant cell arteritis, an inflammatory disease of blood vessels, as a possible big growth driver given the larger addressable market and commercial opportunity, modelled at about $1.6 billion peak sales opportunity.Based on all that KNSA has going for it, Choi assumed coverage by bumping up the rating from Hold to Buy and attaching an $18 price target. This conveys his confidence in the biotech’s ability to climb 58% higher in the next twelve months.It has been pretty quiet on Wall Street when it comes to other analyst activity. As Choi is the only analyst that has published a recommendation in the last three months, KNSA has a Moderate Buy consensus. (See Kiniksa stock analysis on TipRanks)Magenta Therapeutics (MGTA)Magenta, which uses stem cell biology to develop cures for autoimmune diseases, blood cancers and genetic diseases, is definitely promising thanks to its focus on the curative potential of stem cell transplants as well as on the different stages in the transplant process.Additionally, Magenta stands to add value if it can increase the number of patients that are initially eligible for transplants as it would expand the opportunity long-term. Choi believes that the biotech could achieve this with its earliest stage conditioning program given the amount of addressable patients. These assets include C100 and C300, antibody-drug conjugates (ADCs) for transplant conditioning, or the second step in the stem cell transplant process.“Conditioning toxicity is responsible for up to 10% of mortality following allogeneic transplants and limits the number of patients with successful transplants, and even the number of patients initially eligible for transplant. With a targeted conditioning agent, MGTA hopes to only deplete the cell types required for a successful transplant,” Choi explained. As such, the analyst expects that early data for these programs will attract substantial investor attention.However, Choi points out that its assets are mostly in the early stages and require further clinical validation. “In the near-term we think the early stages of its assets may limit share outperformance, especially without more visibility on the commercial potential in these populations,” he wrote.To this end, Choi took over coverage by issuing a Hold rating and setting an $18 price target. At this target, the potential twelve-month gain comes in at 41%.The rest of the Street’s take is more of a mixed bag. With 2 Buys and 1 Hold, the verdict is that MGTA is a Moderate Buy. However, the average price target of $19 puts the upside potential above Choi’s forecast at 49%. (See Magenta stock analysis on TipRanks)Odonate Therapeutics (ODT)The cancer drug maker represents the “the ugly” of the biotech sector according to Choi.That’s not to say that the Goldman Sachs analyst doesn’t see any positives for Odonate Therapeutics. The company has gained 114% since the start of the year, with Choi adding that its tesetaxel drug in HR+/HER2- metastatic breast cancer appears poised for approval.However, the headwinds facing ODT can’t be ignored. “The HR+/HER2- breast cancer market is competitive with many generic taxane and other chemotherapies currently available, which will likely limit commercial adoption, in our view,” Choi stated.On top of this, he predicts that utilization will primarily be in the patient population evaluated in ODT’s Phase 3 CONTESSA study. This lends itself to Choi’s prediction of sales that are about 60% below consensus estimates, on average, for the ﬁrst three years following the launch. As a result, the analyst remains bearish.“Given the signiﬁcant share price appreciation year-to-date, we see the valuation as stretched and look for a more attractive entry point,” Choi concluded.Taking all of this into consideration, Choi initiated his coverage of the biotech with a Sell rating. Given the $26 price target, the four-star analyst sees 14% downside in store.What do other analysts think? Looking at the consensus breakdown, it’s an even split. As 1 Buy and 1 Sell have been received in the last three months, the word on the Street is that ODT is a Hold. In addition, the $26 average stock-price forecast indicates upside potential that’s right in line with Choi’s forecast. (See Odonate stock analysis on TipRanks)
Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDAQ: ...
Biotech stocks advanced in the holiday-shortened week, with upside driven mainly by the broader market strength. Reflecting the extreme volatility in the space, a few stocks gyrated wildly in reaction ...
Legendary investors such as Jeffrey Talpins and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don't publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That's why we analyze the […]
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...